معرفی
Peter Scott is a Professor of Chemistry at the University of Warwick, UK, with a distinguished career spanning over two decades. He serves as Director of the Institute of Advanced Study (2017-), holds a Royal Society Industry Fellowship (2018-), and founded the Warwick spin-out Interface Polymers Ltd. His research bridges molecular self-assembly for biomedical applications and polymer materials development with industrial partners like Infineum.
- Educational Background:
- BSc (Hons) in Applied Chemistry, University of Salford (1988)
- DPhil in Chemistry, University of Oxford (1991)
- Post-doctoral work at Universität Konstanz (Royal Society European Research Fellow) and University of Sussex (Ramsay Memorial Fellow)
Research Focus:
Peter pioneers molecular self-assembly research, developing antimicrobial and anticancer agents through metallohelices that mimic host-defense peptides. His polymer materials work creates interfacially-active materials for recycling, with industry collaborations at Interface Polymers Ltd. and Infineum. Earlier contributions include enantioselective catalysis and lanthanide/actinide chemistry breakthroughs.
Article Trends:
His publications demonstrate sustained innovation across bioinorganic chemistry (metallohelices for DNA targeting), polymer synthesis (block copolymers), and asymmetric catalysis (zirconium complexes). Recurring themes include chirality, self-assembly, and interdisciplinary collaboration with biophysicists and clinicians.
Scientific Recognition:
- Royal Society Industry Fellowship
- Royal Society European Research Fellowship
- McCamley Teaching Excellence Awards (1998, 2007)
- RSC Emerging Technologies Competition Prize (2016)
- Fellow of the Royal Society of Chemistry
- Doctor of Science (DSc), University of Warwick (2008)
Academic Leadership:
As Director of the Institute of Advanced Study, Peter drives interdisciplinary collaboration. He leads Warwick's Business Partnerships Grand Challenge and chairs NMiTE Trustee Board. His lab maintains strong industry ties through Interface Polymers Ltd., with collaborations spanning cancer pharmacology (Roger Phillips), microbiology (Nick Waterfield), and materials science.
